Promising but early data on PD-1 x CTLA-4 bispecifics from Macrogenics and Akeso add further weight to this approach.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
China’s answer to the Asco conference, remarkably now in its 22nd year, reminds western investors of the country’s oncology prowess.